Novo Nordisk Navigates a Critical Year of Launches and Losses

Novo Nordisk launches high-dose Wegovy in US as oral pill attracts new patients. Despite innovations, shares fall amid price cuts and generic competition in India.

The Danish pharmaceutical giant Novo Nordisk is charting a course through a turbulent 2026, marked by significant product launches in the United States and severe competitive pressures emerging from key markets like India. The company's strategy hinges on expanding its blockbuster weight-loss portfolio while defending its core business against generic erosion and pricing headwinds.

A major development this week is the nationwide U.S. launch of Wegovy HD, the highest-strength injectable dose of semaglutid yet available. At 7.2 mg, it significantly outperforms the previous 2.4 mg maximum dose. Clinical data from the STEP-UP study showed participants with obesity achieved an average weight loss of 20.7 percent, with about one-third losing 25 percent or more. For patients with type-2 diabetes, the average reduction was 14.1 percent. The drug is now available in approximately 70,000 U.S. pharmacies.

Simultaneously, early data on the oral Wegovy pill, launched three months ago, provides a crucial commercial insight. It appears to be attracting entirely new patients rather than cannibalizing the injectable business. Many new users had previously avoided GLP-1 therapies due to injection costs or needle phobia, a condition affecting an estimated 25 percent of U.S. adults. In a direct comparison with Eli Lilly's newly approved rival pill Foundayo (orforglipron), the oral Wegovy formulation demonstrated a significantly higher mean weight loss and a discontinuation rate due to side effects roughly 14 times lower.

Beyond obesity care, Novo Nordisk scored a regulatory win in diabetes treatment. In late March, the FDA approved Awiqli, the first long-acting basal insulin for adults with type-2 diabetes requiring only a once-weekly injection. This marks the introduction of the first new basal insulin class in over two decades. A U.S. launch in the familiar FlexTouch pen is scheduled for the second half of 2026.

These advances, however, are set against a stark financial backdrop. The company's shares have fallen approximately 28 percent since the start of the year, currently trading around 32.30 Euros. Management forecasts a currency-adjusted sales decline of 5 to 13 percent for 2026. This pressure stems from U.S. government pricing agreements under the Most-Favored-Nation rule, reduced Medicaid reimbursements for obesity therapies, and the dominance of rival Eli Lilly, which controls over 60 percent of the U.S. market for weight-loss injections.

Competitive intensity is exploding elsewhere. In India, the core patent for semaglutid expired on March 20th. Within 48 hours, over 15 generic versions from local manufacturers flooded the market, causing prices to collapse by up to 90 percent. To remain competitive, Novo Nordisk was forced to slash prices for its own branded products by up to 48 percent and is now pursuing distribution partnerships with Indian firms like Emcure and Abbott India. With further patent expiries looming in Canada, Brazil, and China this year, these dynamics are expected to materially impact revenue.

In response to the share price weakness, the company is executing a share buyback program of up to 15 billion Danish kroner. By early April, nearly 10 million shares had been repurchased under this initiative.

Looking ahead, two key catalysts could shift the narrative. In May, Novo Nordisk will report quarterly results, offering the first glimpse of sales from the oral Wegovy pill. Furthermore, around the turn of the year 2026/2027, the FDA is expected to decide on CagriSema, a combination therapy of cagrilintide and semaglutid for obesity. Analysts at GlobalData project the broader Wegovy portfolio could drive sales from $13.5 billion in 2026 to $18.9 billion by 2031, with the pill contributing an estimated $2.76 billion.